Background: PSP is a neuropathologically defined disease entity. Clinical diagnostic criteria,
published in 1996 by the National Institute of Neurological Disorders and Stroke/Society for …

Cerebral dopamine depletion is the hallmark of Parkinson disease. Because dopamine
modulates ontogenetic neurogenesis, depletion of dopamine might affect neural precursors in …

Progressive supranuclear palsy (PSP) is a movement disorder with prominent tau neuropathology.
Brain diseases with abnormal tau deposits are called tauopathies, the most common …

In Parkinson's disease, nigral dopaminergic neurones degenerate, whereas post‐synaptic
striatal target neurones are spared. In some atypical parkinsonian syndromes, both nigral and …

Progressive supranuclear palsy (PSP) is a 4R-tauopathy predominated by subcortical pathology
in neurons, astrocytes, and oligodendroglia associated with various clinical phenotypes…

Progressive supranuclear palsy (PSP), previously believed to be a common cause of atypical
parkinsonism, is now recognised as a range of motor and behavioural syndromes that are …

In multiple sclerosis (MS), oligodendrocyte and myelin destruction lead to demyelination
with subsequent axonal loss. Experimental demyelination in rodents has highlighted the …

… Günter U. Höglinger has served on the advisory boards for Bristol-Myers Squibb, Sellas,
UCB; has received honoraria for scientific presentations from Elan, GlaxoSmithKline, Roche, …

2-Deoxy-2-[ 18 F]fluoro-d-glucose positron emission tomography (FDG-PET) is widely used
to study cerebral glucose metabolism. Here, we investigated whether the FDG-PET signal is …

It is believed that glycogen synthase kinase‐3 (GSK‐3) hyperphosphorylates tau protein in
progressive supranuclear palsy (PSP). The Tau Restoration on PSP (TAUROS) study was a …